Derek Archila
Stock Analyst at Wells Fargo
(4.09)
# 527
Out of 5,049 analysts
195
Total ratings
53.12%
Success rate
11.86%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Overweight | $123 → $106 | $44.90 | +136.08% | 2 | Nov 5, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $53 → $69 | $60.10 | +14.81% | 9 | Nov 5, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $51 → $81 | $38.05 | +112.91% | 4 | Nov 5, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $27 → $31 | $6.74 | +359.94% | 3 | Oct 30, 2025 | |
| INCY Incyte | Maintains: Overweight | $89 → $97 | $104.24 | -6.95% | 10 | Oct 29, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $22 → $21 | $12.50 | +68.00% | 6 | Oct 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $36 → $30 | $40.65 | -26.20% | 4 | Oct 21, 2025 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $7 → $5 | $6.07 | -17.63% | 12 | Oct 17, 2025 | |
| APLS Apellis Pharmaceuticals | Upgrades: Overweight | $29 → $32 | $19.98 | +60.16% | 13 | Oct 15, 2025 | |
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $10 | $2.39 | +319.29% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.80 | +24.77% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $23.38 | +62.53% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $0.95 | +216.76% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $2.51 | -20.16% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $289 → $295 | $198.51 | +48.61% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $1.30 | +284.62% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $26 | $28.10 | -7.47% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $16 | $9.88 | +61.94% | 7 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $741 → $756 | $853.20 | -11.39% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.64 | +266.77% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $98.55 | +30.90% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $18 | $19.19 | -6.20% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $12.90 | -22.48% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $2.42 | +519.83% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $17.84 | -21.50% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $23.68 | +90.03% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $8.78 | +25.28% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.98 | +236.13% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.58 | +675.19% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.35 | +313.79% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.99 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $31.01 | +522.38% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $67.56 | -39.31% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $15.70 | +919.11% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $15.16 | +295.84% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.42 | +556.85% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.10 | +4,466.21% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $20.57 | +147.93% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $14.67 | +499.86% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $21.86 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $24.25 | - | 2 | Aug 3, 2017 |
Soleno Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $123 → $106
Current: $44.90
Upside: +136.08%
Kymera Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $53 → $69
Current: $60.10
Upside: +14.81%
AnaptysBio
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $38.05
Upside: +112.91%
Kyverna Therapeutics
Oct 30, 2025
Maintains: Overweight
Price Target: $27 → $31
Current: $6.74
Upside: +359.94%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $89 → $97
Current: $104.24
Upside: -6.95%
Nurix Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $22 → $21
Current: $12.50
Upside: +68.00%
Exelixis
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $40.65
Upside: -26.20%
Kezar Life Sciences
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.07
Upside: -17.63%
Apellis Pharmaceuticals
Oct 15, 2025
Upgrades: Overweight
Price Target: $29 → $32
Current: $19.98
Upside: +60.16%
C4 Therapeutics
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.39
Upside: +319.29%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.80
Upside: +24.77%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $23.38
Upside: +62.53%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.95
Upside: +216.76%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.51
Upside: -20.16%
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $198.51
Upside: +48.61%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.30
Upside: +284.62%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $28.10
Upside: -7.47%
Aug 7, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $9.88
Upside: +61.94%
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $853.20
Upside: -11.39%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $4.64
Upside: +266.77%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $98.55
Upside: +30.90%
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $19.19
Upside: -6.20%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $12.90
Upside: -22.48%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $2.42
Upside: +519.83%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $17.84
Upside: -21.50%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $23.68
Upside: +90.03%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $8.78
Upside: +25.28%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.98
Upside: +236.13%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.58
Upside: +675.19%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $4.35
Upside: +313.79%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.99
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $31.01
Upside: +522.38%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $67.56
Upside: -39.31%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $15.70
Upside: +919.11%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $15.16
Upside: +295.84%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.42
Upside: +556.85%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.10
Upside: +4,466.21%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $20.57
Upside: +147.93%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $14.67
Upside: +499.86%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $21.86
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $24.25
Upside: -